Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Blood. 2010 Feb 11;115(6):1280-7. doi: 10.1182/blood-2009-07-230680. Epub 2009 Dec 10.
Previous studies have indicated that blockade of signaling through the T-cell receptor (TCR)/calcineurin/nuclear factor of activated T cells (NFAT) pathway impairs transplantation tolerance induced with anti-CD154 antibody. By using an allogeneic bone marrow transplantation model, we examined the role of the TCR/calcineurin/NFAT pathway for tolerance induction with anti-CD154. Calcineurin blockade by cyclosporine A led to a failure of CD8 but not CD4 tolerance, and experiments in NFAT1(-/-) mice replicated this effect. Studies in thymectomized mice demonstrated that blockade of the calcineurin/NFAT pathway after bone marrow transplantation led to a failure of peripheral CD8 tolerance. Moreover, CD8 adoptive transfer studies demonstrated that NFAT1 is cell-intrinsically required for peripheral CD8 tolerance. NFAT1 deficiency did not impair CD8 T-cell up-regulation of PD1, which is required for CD8 tolerance in this model. NFAT1 has previously been shown to have a role in CD4 cells for anergy induction and for programming CD4 cells to become regulatory cells. By generating mice lacking NFAT1 in CD4 but not CD8 cells, we demonstrate that NFAT1 is neither required for CD4 tolerance induction nor for their regulatory function on CD8 T cells. Thus, our study reveals a CD8 T cell-intrinsic NFAT1 requirement for CD8 tolerance in vivo.
先前的研究表明,阻断 T 细胞受体 (TCR)/钙调神经磷酸酶/活化 T 细胞核因子 (NFAT) 通路的信号传导会损害抗 CD154 抗体诱导的移植耐受。通过使用同种异体骨髓移植模型,我们研究了 TCR/钙调神经磷酸酶/NFAT 通路在抗 CD154 诱导耐受中的作用。环孢素 A 抑制钙调神经磷酸酶导致 CD8 但不导致 CD4 耐受,而 NFAT1(-/-) 小鼠的实验复制了这一效应。胸腺切除术小鼠的研究表明,骨髓移植后钙调神经磷酸酶/NFAT 通路的阻断导致外周 CD8 耐受失败。此外,CD8 过继转移研究表明,NFAT1 是外周 CD8 耐受所必需的。NFAT1 缺乏并不损害 PD1 在 CD8 T 细胞中的上调,这是该模型中 CD8 耐受所必需的。NFAT1 先前已被证明在 CD4 细胞中具有诱导失能和编程 CD4 细胞成为调节性细胞的作用。通过生成缺乏 NFAT1 的 CD4 但不缺乏 CD8 细胞的小鼠,我们证明 NFAT1 既不是 CD4 耐受诱导所必需的,也不是其对 CD8 T 细胞的调节功能所必需的。因此,我们的研究揭示了体内 CD8 T 细胞内在的 NFAT1 对 CD8 耐受的需求。